Видео ютуба по тегу Stephan Grupp

Revolutionizing Cancer Care: Insights from CAR-T therapy Pioneer Dr. Stephan Grupp
Revolutionizing Cancer Care: Insights from CAR-T therapy Pioneer Dr. Stephan Grupp
Immunotherapy: CAR-T Cells - Stephan Grupp, MD, PhD
Immunotherapy: CAR-T Cells - Stephan Grupp, MD, PhD
Stephan Grupp discussing his work at the University of Pennsylvania
Stephan Grupp discussing his work at the University of Pennsylvania
Extra Minutes | Dr. Stephan Grupp discussing when his medical trial will be available in Australia.
Extra Minutes | Dr. Stephan Grupp discussing when his medical trial will be available in Australia.
Part 1: Kymriah - First FDA Approved Gene Therapy, Dr. Stephan Grupp [20 min]
Part 1: Kymriah - First FDA Approved Gene Therapy, Dr. Stephan Grupp [20 min]
Trends in inpatient and ICU resource utilization after CAR-T in pediatric ALL
Trends in inpatient and ICU resource utilization after CAR-T in pediatric ALL
Gene Therapy for Children: A Conversation with Prof. Stephan Grupp | Dr. Zainul Aabideen | EPBMT2024
Gene Therapy for Children: A Conversation with Prof. Stephan Grupp | Dr. Zainul Aabideen | EPBMT2024
The CAR-T Revolution 3 Years After FDA Approval
The CAR-T Revolution 3 Years After FDA Approval
Stephan Grupp, The Children's Hospital of Philadelphia
Stephan Grupp, The Children's Hospital of Philadelphia
Beating Leukemia with Groundbreaking CAR T Cell Therapy with Dr Stephan A Grupp Full
Beating Leukemia with Groundbreaking CAR T Cell Therapy with Dr Stephan A Grupp Full
CHOP's Dr. Stephan Grupp Accepts Community Service Award
CHOP's Dr. Stephan Grupp Accepts Community Service Award
Part 1 - Kymriah-First FDA Approved Gene Therapy, Dr Stephan Grupp (20 min)
Part 1 - Kymriah-First FDA Approved Gene Therapy, Dr Stephan Grupp (20 min)
Grupp: Chimeric T-Cell Therapy for Leukemia
Grupp: Chimeric T-Cell Therapy for Leukemia
Stephan A. Grupp: Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients ...
Stephan A. Grupp: Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients ...
ASH 2017 highlights: Cell therapy approaches in ALL
ASH 2017 highlights: Cell therapy approaches in ALL
Extra Minutes | Dr. Stephan Grupp discussing how HIV is modified to cure cancer.
Extra Minutes | Dr. Stephan Grupp discussing how HIV is modified to cure cancer.
Real world experience of tisagenlecleucel for R/R ALL in the US
Real world experience of tisagenlecleucel for R/R ALL in the US
ASH2014: Stephan A. Grupp - CAR targeting CTL019 in Children with Relapsed, Refractory ALL
ASH2014: Stephan A. Grupp - CAR targeting CTL019 in Children with Relapsed, Refractory ALL
Part 3: CHOP FDA Roundtable ft. Stephan Grupp, MD, Sarah McCague, MS, and Chip Smith, DVM [17 min]
Part 3: CHOP FDA Roundtable ft. Stephan Grupp, MD, Sarah McCague, MS, and Chip Smith, DVM [17 min]
Identifying relapse in B-ALL patients treated with tisagenlecleucel using MRD
Identifying relapse in B-ALL patients treated with tisagenlecleucel using MRD